NYPOZI
Growthfilgrastim-txid
BLAINJECTIONINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NYPOZI (filgrastim-txid) is colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. First approved in 2024.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYPOZI (filgrastim-txid) is a recombinant human granulocyte colony-stimulating factor (G-CSF) approved in June 2024. It stimulates neutrophil production and function by binding to cell surface receptors on hematopoietic cells, enhancing proliferation, differentiation, and immune cell activation. This biosimilar or authorized generic addresses chemotherapy-induced neutropenia and related neutrophil deficiencies.
Growth
Early-stage growth product with moderate competitive pressure (30) suggests building teams in sales, market access, and brand management to establish presence in the supportive oncology space.
Mechanism of Action
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is…
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NYPOZI offers early-career and mid-career opportunities in a high-velocity launch environment focused on capturing share in the supportive oncology market. Roles emphasize commercial execution, competitive positioning, and payer strategy rather than clinical innovation or long-term franchise building.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.